Navigation Links
Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
Date:5/26/2009

PRINCETON, N.J., May 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a conference call and live webcast at 4:00 p.m. Eastern Time on Tuesday, June 2, 2009. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex will provide an update and recent highlights from Medarex's pipeline.

The webcast of the live event and archive can be accessed through the Investor Relations section of Medarex's website at www.medarex.com. To access the call live, please dial 1-877-874-1567 (U.S./Canada) or 1-719-325-4768 (international).

An archived telephonic replay of the conference call will be available until midnight Eastern Time on June 9, 2009. Access numbers for this replay are 1-888-203-1112 (U.S./Canada) or 1-719-457-0820 (international); the replay passcode is 4826956.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently approved for commercial sale, the subject of regulatory applications for marketing authorization, or in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces 2009 First Quarter Financial Results
2. Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009
3. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
4. Medarex to Present at the Needham Cancer Therapeutics Conference
5. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
6. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
7. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. Medarex to Present at the RBC Capital Markets Healthcare Conference
9. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
10. Medarex Announces 2008 Third Quarter Financial Results
11. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... Linda, Ca (PRWEB) , ... August 14, 2017 ... ... for poorly characterized and performing antibodies. Key researchers in the antibody community have ... proper characterization and consistency for antibodies in the laboratory. , The ...
(Date:8/11/2017)... Aug. 11, 2017  Market researcher Kalorama ... Times article regarding the telemedicine market.  The ... Kalorama Information.  The article, "Heart and ...  used information from Kalorama Information,s Remote ... Telemedicine Market  (Sleep, Diabetes, Vital Signs ...
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... ... food production, and, in particular, more natural alternatives to synthetic ingredients,” said Matt ... of Third Wave, with the established manufacturing presence and know-how of Biorigin will ...
(Date:8/10/2017)... ... August 09, 2017 , ... The era ... clinic is here. The team at Capricor Therapeutics, Inc. utilized a cardiosphere-derived stem-like ... studies. , Dr. Travis Antes, head of analytical development at Capricor Therapeutics ...
Breaking Biology Technology:
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Biology News(10 mins):